23andMe Releases New FDA-Cleared Genetic Report On Simvastatin, A Commonly Prescribed Statin
Portfolio Pulse from Benzinga Newsdesk
23andMe has released a new FDA-cleared genetic report on Simvastatin, a commonly prescribed statin. This makes 23andMe the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports.
July 20, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
23andMe's new FDA-cleared genetic report on Simvastatin could potentially increase the company's market share in the genetic testing industry.
The release of a new FDA-cleared genetic report on Simvastatin by 23andMe could potentially increase the company's market share in the genetic testing industry. This is because the report could attract more consumers who are interested in understanding their genetic response to commonly prescribed medications like Simvastatin. The fact that 23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports could also give it a competitive advantage in the industry.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100